

# Artuela Ñaku

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6934242/publications.pdf>

Version: 2024-02-01

9  
papers

400  
citations

1307594

7  
h-index

1474206

9  
g-index

9  
all docs

9  
docs citations

9  
times ranked

674  
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of lipid rafts cholesterol with clinical profile in fragile X syndrome. Scientific Reports, 2022, 12, 2936.	3.3	4
2	The safety and efficacy of metformin in fragile X syndrome: An open-label study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 110, 110307.	4.8	13
3	Combining Lovastatin and Minocycline for the Treatment of Fragile X Syndrome: Results From the LovaMiX Clinical Trial. Frontiers in Psychiatry, 2021, 12, 762967.	2.6	6
4	Implication of hypocholesterolemia in autism spectrum disorder and its associated comorbidities: A retrospective caseâ€“control study. Autism Research, 2019, 12, 1860-1869.	3.8	18
5	Ser-Phosphorylation of PCSK9 (Proprotein Convertase Subtilisin-Kexin 9) by Fam20C (Family With Tj ETQq1 1 0.784314 rgBT /Overlook	2.4	36
6	Lipoprotein(a) Levels and the Risk of Myocardial Infarction Among 7 Ethnic Groups. Circulation, 2019, 139, 1472-1482.	1.6	196
7	New insights of altered lipid profile in Fragile X Syndrome. PLoS ONE, 2017, 12, e0174301.	2.5	26
8	Lovastatin corrects ERK pathway hyperactivation in fragile X syndrome: potential of plateletâ€™s signaling cascades as new outcome measures in clinical trials. Biomarkers, 2016, 21, 497-508.	1.9	39
9	Effect of lovastatin on behavior in children and adults with fragile X syndrome: An openâ€“label study. American Journal of Medical Genetics, Part A, 2014, 164, 2834-2842.	1.2	62